Today: 29 June 2026
Browse Category

NASDAQ:IONS 22 August 2025 - 25 August 2025

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····

Stock Market Today

  • Fluor's Russell Index Additions and Pharma Feasibility Studies Could Shift Investment Outlook
    June 29, 2026, 12:41 AM EDT. Fluor Corporation (NYSE: FLR) was added to multiple Russell growth indexes in June 2026, boosting its visibility in key equity benchmarks. Concurrently, it began feasibility studies for Voyageur Pharmaceuticals on an iodine project linked to Bayer and a new contrast media manufacturing facility in North America. These moves might broaden Fluor's market exposure beyond its traditional engineering and construction segments. While the developments support Fluor's backlog and diversification story, analysts caution the near-term focus remains on managing execution risks and cash flow volatility. Fluor projects $18.3 billion revenue and $443.4 million earnings by 2029, requiring steady growth amid potential cost and labor challenges. Investor opinions vary, with some seeing upside potential beyond current valuations, while others stress caution due to operational risks.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop